Table 1.

Demographic characteristics and rheumatoid arthritis (RA) history of users of anti-tumor necrosis factor (anti-TNF) medications and nonusers.

Characteristic	Anti-TNF Use, n = 104 cases	No Anti-TNF Use, n = 164 cases	T test or Chi-square p
Age, yrs, mean ± SD	58.7 ± 12.4	64.4 ± 10.5	< 0.0001
Sex female, %	84	90	0.15
Body mass index, mean ± SD	28.7 ± 6.3	28.3 ± 6.3	0.64
RA flare rate, %	26 (n = 77)	20 (n = 121)	0.31
VAS pain score 6+ mo postsurgery on survey	34.8 ± 27.7	40.1 ± 27.1	0.16
Prednisone use, %	27	37	0.10
Prednisone dose at time of surgery, mg, mean ± SD	7 ± 3.3	7.5 ± 4.8	0.59
Perioperative stress dose steroid use, %	26	26	0.73
Duration of RA reported at time of survey, yrs, mean ± SD	21.5 ± 16.3	19.5 ± 12.4	0.32
Elixhauser comorbidity score*, mean ± SD	2.1 ± 1.3	2.2 ± 1.4	0.37
Nonbiologic DMARD use, %	64 (n = 67)	70 (n = 115)	0.33
WOMAC function score, range 0–100, mean ± SD, n = 179	43.6 ± 20.3	43.7 ± 18.61	0.96
Euroqol (EQ-5D), range −1 to 1, mean ± SD (n = 214)	0.58 ± 0.21	0.58 ± 0.20	0.95
SF-36 function score, mean ± SD (n = 208)	29.2 ± 7.3	29.1 ± 8.2	0.92

^*Elixhauser comorbidity score estimates probability of death in hospital based on comorbid diseases; higher scores indicate greater burden of comorbid diseases. VAS: visual analog scale; WOMAC: Western Ontario and McMaster Universities Arthritis Index; SF-36: Medical Outcomes Study Short Form-36; DMARD: disease-modifying antirheumatic drug.